Minimally Invasive Surgery for Stomach Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores two surgical approaches for treating gastric and gastroesophageal junction (GEJ) cancers. Researchers compare minimally invasive partial stomach removal (MIPG) with complete stomach removal (MITG) to determine which leads to better patient outcomes. Participants will complete questionnaires before and after surgery to provide insights into recovery and quality of life. Individuals with a confirmed diagnosis of non-spreading gastric or GEJ cancer scheduled for one of these surgeries may be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these surgical techniques are safe for patients with GEJ adenocarcinoma?
Research has shown that minimally invasive proximal gastrectomy (MIPG) is generally safe for individuals with advanced stomach cancer. Studies have found that this surgery, often performed after chemotherapy, is feasible and well-tolerated. Patients undergoing this procedure reported fewer complications compared to more invasive methods. Although the surgery might take slightly longer, it typically results in less blood loss and a shorter hospital stay. Overall, evidence suggests that MIPG is a reliable option for treating stomach and gastroesophageal junction cancers.12345
Why are researchers excited about this trial?
Researchers are excited about the trial comparing minimally invasive proximal gastrectomy (MIPG) to minimally invasive total gastrectomy (MITG) for gastric and gastroesophageal junction cancers because it explores a potentially less extensive surgical option. Unlike the standard total gastrectomy, which removes the entire stomach, MIPG only involves removing the upper part. This might lead to better preservation of stomach function, potentially improving the patient's quality of life. Additionally, because MIPG is minimally invasive, it may result in quicker recovery times and fewer complications, making it a promising alternative to the more extensive surgery.
What evidence suggests that this trial's procedures could be effective for GEJ adenocarcinoma?
Research has shown that minimally invasive proximal gastrectomy (MIPG), which participants in this trial may undergo, can be as effective as open surgery for treating stomach cancer. Studies have found that laparoscopic surgery, using small incisions, offers survival rates similar to traditional open surgery. This method often results in a shorter hospital stay, averaging 7 days, and a lower complication rate of about 12.2%. Although the number of lymph nodes removed, crucial for determining cancer stage, might be lower, survival outcomes remain similar. These findings suggest that MIPG could be a promising option for patients with gastroesophageal junction (GEJ) adenocarcinoma. Meanwhile, another group in this trial will undergo minimally invasive total gastrectomy (MITG), serving as the standard of care/control group.45678
Who Is on the Research Team?
Vivian Strong, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-Surgery Assessment
Participants complete a questionnaire 1 month before the surgical procedure
Surgery
Participants undergo either minimally invasive proximal gastrectomy (MIPG) or minimally invasive total gastrectomy (MITG)
Follow-up
Participants complete questionnaires and are monitored for safety and effectiveness at 1, 3, 6, and 12 months after surgery
What Are the Treatments Tested in This Trial?
Interventions
- Minimally Invasive Proximal Gastrectomy
- Minimally Invasive Total Gastrectomy
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will undergo MITG (Standard of Care/Control Group)
Participants will undergo MIPG (Trial Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Citations
Minimally Invasive and Open Gastrectomy for Gastric Cancer
Overall, 31.8% of included studies reported outcomes for analysis in relation to OS (7/22). The mean follow-up was 56.4 months (range 22.1–99.8 ...
Long-term oncological outcomes of minimally invasive ...
Laparoscopic gastrectomy, while associated with a lower lymph node yield, provides similar overall survival rates compared to open surgery.
A Study of Minimally Invasive Proximal Gastrectomy Versus ...
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers.
4.
acsjournals.onlinelibrary.wiley.com
acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34440Surgical considerations and outcomes of minimally invasive ...
Laparoscopic gastrectomy (LG) showed early promise with short-term outcomes, and the 2014 Japanese national guidelines recommended the ...
Minimally invasive surgery for gastric cancer in USA
In terms of postoperative outcomes, the average length of hospital stay was 7 days, postoperatively morbidity was 12.2%, and postoperative mortality was 4.1%.
Safety and feasibility of minimally invasive gastrectomy ...
Minimally invasive gastrectomy following preoperative chemotherapy was feasible and safe for patients with highly advanced gastric cancer.
7.
bmcgastroenterol.biomedcentral.com
bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-024-03155-5Safety and feasibility of minimally invasive gastrectomy ...
Minimally invasive gastrectomy following preoperative chemotherapy was feasible and safe for patients with highly advanced gastric cancer.
Transpacific multicenter collaborative study of minimally ...
Results: Among 71 patients with P/GEJ cancers enrolled from 2022 through 2024, 64 underwent either MITG (n = 26, 41%) or MIPG (n = 38, 59%). ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.